Status:
RECRUITING
Augmenting Standard-of-care Treatment of Plaque Psoriasis by Neuromodulation
Lead Sponsor:
Burrell College of Osteopathic Medicine
Conditions:
Psoriasis Vulgaris
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The human body responds to inflammation, such as psoriatic skin lesions, by activating the cholinergic anti-inflammatory pathway. In patients with plaque psoriasis, this pathway is not sufficient to c...
Detailed Description
An estimated 20% of psoriasis patients experience treatment failure. Afferent vagal nerve fibers that are part of the anti-inflammatory reflex sense inflammation, such as psoriatic skin lesions. The i...
Eligibility Criteria
Inclusion
- 18 years or older
- Plaque psoriasis diagnosed by a dermatologist
Exclusion
- pregnancy
- vestibulocochlear neuronitis or nerve damage
- cardiac arrhythmia
- epilepsy
- anticipated change in medication during the 3-month study period
Key Trial Info
Start Date :
April 26 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 28 2026
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT05243303
Start Date
April 26 2022
End Date
February 28 2026
Last Update
July 10 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Burrell College of Osteopathic Medicine
Las Cruces, New Mexico, United States, 88001